Locus Biosciences, Inc.
Locus is a clinical-stage biotechnology company developing precision medicines for therapeutic indications across infectious disease and inflammatory diseases. Once revolutionary, antibiotics are interfering with the effectiveness of novel, life-saving therapies and causing disease by disrupting the microbiome. The need to address infections with stronger antibiotics also has physicians weighing antibiotic toxicities in patients. Our vision is to revolutionize the treatment of disease and our crPhage™ and ePhage platforms decrease the burden of medicines on that patient to treat their disease. We completed a first-of-its-kind controlled clinical trial in January 2021, with a crPhage product targeting Escherichia coli bacteria causing urinary tract infections. We are continuing to advance our company into Phase 2 human efficacy trials with the support of our incredible partners.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
About Us
Starting in Infectious Disease, Locus is strategically pursuing additional, more complex therapeutic areas as we continue to expand our precision therapeutics platform
Partnering With Us
Our broad, agile platform allows partners to bring a new problem to us so that we can collaborate and help develop a solution.
Built on the belief that execution is critical in every aspect of the business, we apply standard project management methodologies to everything from science to sales. By timeboxing innovation, we ensure that our deadlines are met, and our iterative process delivers solutions, every time. Whether we are advancing our own assets or developing novel products with our partners, we apply the same approach, each time from start to finish. This standardized, agile approach is at the core of who we are and how we approach partnerships.